DDInter1845 DDInter1934
A propylamine formed from the cyclization of the side chain of amphetamine. This monoamine oxidase inhibitor is effective in the treatment of major depression, dysthymic disorder, and atypical depression. It also is useful in panic and phobic disorders (From AMA Drug Evaluations Annual, 1994, p311). Tranylcypromine is a racemate comprising equal amounts of (1R,2S)- and (1S,2R)-2-phenylcyclopropan-1-amine with the chiral centers both located on the cylopropane ring. An irreversible monoamine oxidase inhibitor that is used as an antidepressant (INN tranylcypromine).
Vilanterol is a selective long-acting β2-adrenergic agonist (LABA) with inherent 24-hour activity for the once-daily treatment of COPD and asthma. This is in response to the need for longer-acting β2-adrenergic agonists to overcome poor patient compliance (due to the frequency of dosing regimens or complexities of drug administration). Vilanterol was designed based on the salmeterol molecular scaffold, particularly as a antedrug analog of salmeterol modification by modifying the salmeterol molecule to create homochiral compounds with the (R)-configuration. Vilanterol is 1000 and 400 fold more selective for β2 than β1 and β3 adrenoceptors, respectively, with a faster onset of action than salmeterol. Additionally, vilanterol demonstrated a significantly longer duration of action than salmeterol, with the bronchodilator effect still apparent at 22h. Vilanterol's pharmacological effect is attributable to stimulation of intracellular adenylyl cyclase which catalyzes the conversion of adenosine triphosphate (ATP) to cyclic-3',5'-adenosine monophosphate (cAMP). Increases in cyclic AMP are associated with the relaxation of bronchial smooth muscle and inhibition of the release of hypersensitivity mediators from mast cells in the lungs.[A7738,A259961] Vilanterol is approved for use in several combination products such as with [fluticasone furoate] under the tradename BREO ELLIPTA, with [umeclidinium bromide] as ANORO ELLIPTA, and with both [fluticasone furoate] and [umeclidinium bromide] under the trade name TRELEGY ELLIPTA.[L46481,L44461,L44456] BREO ELLIPTA is the first vilanterol-containing product to be approved by the FDA in May 2013, followed by ANORO ELLIPTA in December 2013 and TRELEGY ELLIPTA in September 2020.[L46876,L46881,L46886] Although all 3 products are approved for the maintenance treatment of chronic obstructive pulmonary disease (COPD), only TRELEGY ELLIPTA and BREO ELLIPTA are approved for maintenance treatments of asthma in patients aged 18 years and older and 5 years and older respectively.[L46481,L44461,L44456]
Tranylcypromine {u} (Compound) resembles {v} (Compound) Phenelzine
Phenelzine {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Vilanterol
Tranylcypromine {u} (Compound) resembles {v} (Compound) Phendimetrazine
Phendimetrazine {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Vilanterol
Tranylcypromine {u} (Compound) resembles {v} (Compound) Phenelzine
Phenelzine {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Insulin degludec
Insulin degludec {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Vilanterol
Tranylcypromine {u} (Compound) resembles {v} (Compound) Phendimetrazine
Phendimetrazine {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Insulin degludec
Insulin degludec {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Vilanterol
Tranylcypromine {u} (Compound) resembles {v} (Compound) Phenylpropanolamine
Phenylpropanolamine {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Methylphenidate
Methylphenidate {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Vilanterol
Tranylcypromine {u} (Compound) resembles {v} (Compound) Dextroamphetamine
Dextroamphetamine {u} (Compound) resembles {v} (Compound) Selegiline
Selegiline {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Vilanterol
Tranylcypromine {u} (Compound) resembles {v} (Compound) Fencamfamine
Fencamfamine {u} (Compound) resembles {v} (Compound) Phendimetrazine
Phendimetrazine {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Vilanterol
Tranylcypromine {u} (Compound) resembles {v} (Compound) Amphetamine
Amphetamine {u} (Compound) resembles {v} (Compound) Selegiline
Selegiline {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Vilanterol
Tranylcypromine {u} (Compound) resembles {v} (Compound) Phendimetrazine
Phendimetrazine {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Empagliflozin
Empagliflozin {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Vilanterol
Tranylcypromine {u} (Compound) resembles {v} (Compound) Phentermine
Phentermine {u} (Compound) resembles {v} (Compound) and {u} may lead to a major life threatening interaction when taken with {v} Selegiline
Selegiline {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Vilanterol
Tranylcypromine (Compound) resembles Phenelzine (Compound) and Phenelzine may cause a moderate interaction that could exacerbate diseases when taken with Vilanterol
Tranylcypromine (Compound) resembles Phendimetrazine (Compound) and Phendimetrazine may cause a moderate interaction that could exacerbate diseases when taken with Vilanterol
Tranylcypromine (Compound) resembles Phenelzine (Compound) and Phenelzine may cause a moderate interaction that could exacerbate diseases when taken with Insulin degludec and Insulin degludec may cause a moderate interaction that could exacerbate diseases when taken with Vilanterol
Tranylcypromine (Compound) resembles Phendimetrazine (Compound) and Phendimetrazine may cause a moderate interaction that could exacerbate diseases when taken with Insulin degludec and Insulin degludec may cause a moderate interaction that could exacerbate diseases when taken with Vilanterol
Tranylcypromine (Compound) resembles Phenylpropanolamine (Compound) and Phenylpropanolamine may cause a moderate interaction that could exacerbate diseases when taken with Methylphenidate and Methylphenidate may cause a moderate interaction that could exacerbate diseases when taken with Vilanterol
Tranylcypromine (Compound) resembles Dextroamphetamine (Compound) and Dextroamphetamine (Compound) resembles Selegiline (Compound) and Selegiline may cause a moderate interaction that could exacerbate diseases when taken with Vilanterol
Tranylcypromine (Compound) resembles Fencamfamine (Compound) and Fencamfamine (Compound) resembles Phendimetrazine (Compound) and Phendimetrazine may cause a moderate interaction that could exacerbate diseases when taken with Vilanterol
Tranylcypromine (Compound) resembles Amphetamine (Compound) and Amphetamine (Compound) resembles Selegiline (Compound) and Selegiline may cause a moderate interaction that could exacerbate diseases when taken with Vilanterol
Tranylcypromine (Compound) resembles Phendimetrazine (Compound) and Phendimetrazine may cause a moderate interaction that could exacerbate diseases when taken with Empagliflozin and Empagliflozin may cause a moderate interaction that could exacerbate diseases when taken with Vilanterol
Tranylcypromine (Compound) resembles Phentermine (Compound) and Phentermine (Compound) resembles Selegiline (Compound) and Phentermine may lead to a major life threatening interaction when taken with Selegiline and Selegiline may cause a moderate interaction that could exacerbate diseases when taken with Vilanterol